VahatiCor, Inc.
StreetZero Signal 71
About VahatiCor, Inc.
VahatiCor, Inc. is a medtech company transforming cardiac care for patients with Coronary Microvascular Dysfunction (CMD). The company develops the A-FLUX® Reducer System, a catheter-based therapy targeting CMD, a condition affecting millions with limited treatment options. It is a T45 Labs portfolio company based in Santa Clara, California, currently advancing its SERRA-I early-feasibility study.
LATEST FUNDINGSeries B
$30.4M
Announced 2026-10-20
TOTAL RAISED$23M
IN THE NEWS
- 🔗 VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction. - VahatiCor
- 🔗 VahatiCor Inc raises $23M for A-FLUX therapy for CMD | S3 Ventures posted on the topic | LinkedIn
- 🔗 VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction.
- 🔗 VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction. — S3 Ventures: Born in Texas, Investing Nationwide
- 🔗 VahatiCor 2026 Company Profile: Valuation, Funding & Investors | PitchBook
EMPLOYEES—
FOUNDED—
HQSanta Clara, CA, USA
Industry
Other Health Care
Tags
MedtechCardiac CareSeries BMedical Devices
Investors
Key highlights
- Closed $23M Series B led by S3 Ventures to advance A-FLUX therapy.
- Focuses on Coronary Microvascular Dysfunction with limited existing treatments.
- Advancing SERRA-I early-feasibility study and regulatory preparations.
- Portfolio company of T45 Labs with support from strategic investor.
Ask StreetZero about VahatiCor, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account